Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review.

Access to biologic DMARDs for RA is often restricted to those with severe disease. This systematic review aimed to identify prognostic factors in patients with moderate disease activity who may be at risk of disease progression and poor clinical outcomes.